Our Science
Our Approach
Defined Bacterial Consortia
Product Engine
Manufacturing
Intellectual Property
Scientific Insights
Publications
Pipeline & Programs
Pipeline
VE303
VE707
Commitment to Patients
Our Focus
How It Works
Disease Areas
C. difficile
Infection
Clinical Trials
RESTORATiVE303
Expanded Access Policy
Who We Are
Company
Mission
Leadership
Team
Board of Directors
Scientific Advisory Board
Partnerships
Careers
Working at Vedanta
Open Positions
News
Press Releases
Our Science
Defined Bacterial Consortia
Product Engine
Manufacturing
Intellectual Property
Publications
Pipeline & Programs
Pipeline
VE303
VE707
Commitment to Patients
How It Works
C. difficile
Infection
RESTORATiVE303
Expanded Access Policy
Who We Are
Mission
Leadership
Team
Board of Directors
Scientific Advisory Board
Partnerships
Working at Vedanta
Open Positions
News
Press Releases
Press Releases
Year
All
2026
2025
2024
2023
2022
April 2, 2026
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent
C. difficile
Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
Load More
Sorry, nothing found in this query
